Cell therapies represent an important advancement in our ability to treat difficult cancers, but continued exploration of this new modality will require new digital tools and equipment.
- PUPSIT In Cell & Gene Therapy: Risk Reduction Or Operational Complexity?
- Is Your AI Model Trustworthy And Credible In GMP Processes?
- May 2026 — CDMO Opportunities And Threats Report
- In Vivo Gene Editing Is Moving From Promise To Proof
- Why Improving Drug Delivery Remains A Major Opportunity In Oncology
- FDA's Guidance On Cell And Gene CMC Codifies Flexibility
- Strategic Synthesis Of ASGCT And ASCO 2026
- Emerging Technologies In Aseptic Processing: Hype Vs. Operational Reality
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Cell Retention Technology And Specialized Cell Culture Media
Explore how perfusion technology is transforming upstream bioprocessing by boosting productivity, reducing costs, and enabling process intensification while overcoming cell retention challenges.
-
Expanding Translational Research Concepts With Genedata Profiler
The biopharma industry leverages Genedata Profiler to integrate, curate, and analyze diverse R&D data, enabling collaborative, compliant, and AI-driven translational research to optimize drug development.
-
A High-Throughput Platform For Fast And Reliable Clone Screening
The Cydem VT platform consists of several technologies allowing for the cultivation and monitoring of CHO cells in cell line development. Find out how to set up your experiment on this device.
-
Immunophenotyping Of Normal Whole Blood Using A 12-Color BD Horizon™ Chroma Research Panel On The BD FACSDuet™ Premium Sample Preparation System Integrated With The BD FACSLyric™ Flow Cytometer
In this study, a fully automated workflow utilizing the BD FACSDuet™ Premium Sample Preparation System integrated with the BD FACSLyric™ Flow Cytometer was assessed and compared to manual processing.
-
Rapidly Assess Drug Response In 2D And 3D Breast Cancer Model Systems
For years, 2D cell cultures have been crucial in drug discovery. Explore how 3D cultures offer more biologically relevant models today that enhance cancer research and drug efficacy assessments.
-
How Can I Increase My Viral Titers And Improve The Percentage Of Full AAVs?
Explore various strategies to enhance viral titer and increase the percentage of full AAV capsids, like modifications to transfection reagents, cell lines, media, procedures, and more.
-
Navigating The Cell And Gene Regulatory Landscape
Navigating the complex regulatory landscape is essential for cell and gene therapy success. Explore key considerations, challenges, and best practices for companies operating in this space.
-
Early Discovery Of Functional Antibody Leads
Early functional screening accelerates therapeutic antibody discovery, improving hit rates and efficiency through advanced platforms like hybridoma upgrades, single B cell workflows, and tailored phage display strategies.
-
Accelerating Clinical Data Review With Traceable Workflows
Clinical data review needs centralized access and traceable workflows. Leveraging AI-automation and real-time collaboration drives faster, better-informed decisions and reduced compliance risk.
-
5 Steps To Design A Microbiological Performance Qualification For Facilities
Explore five steps to design an EMPQ for sterile manufacturing: classification, protocol drafting, cleaning evaluation, disinfectant efficacy testing, and continuous improvement.
NEWSLETTER ARCHIVE
- 06.26.26 -- Reimagining In Vivo Gene Editing Through Base Editing And Targeted Delivery
- 06.25.26 -- Fixing The Fragmentation In Outsourced Pharma
- 06.25.26 -- Better Biopharma's Editors' Roundtable — A Midyear Look At The 2026 Life Sciences Industry
- 06.24.26 -- Smarter risk management for single-use and filtration systems.
- 06.24.26 -- What's Driving Cell & Gene Therapy Forward? Key Trends & Insights
- In Vivo Gene Editing Is Moving From Promise To Proof
- Driving Gene Therapy Beyond Rare Disease Will Define The Next Era Of CGT
- CGT Manufacturing Shifts From Capacity To Strategy
- Dr. Peter Marks On Why Gene Therapy May Need A New Regulatory Playbook
- Regeneron Advances In Vivo Gene Therapy For Hearing Loss
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections